ArticleMolecular and clinical oncology2025
Simultaneous intravascular large B‑cell lymphoma and papillary thyroid carcinoma: A case report.
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intravascular Lymphoma Associated with the Female Genital Tract-Diagnostic Considerations, Therapeutic Approaches, and Outcomes.Diseases (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of B-cell lymphoma. The concurrence of IVLBCL and papillary thyroid carcinoma (PTC) is extremely rare. A 63-year-old woman was diagnosed with double-expression IVLBCL that presented as a hemophagocytic syndrome, complicated by PTC. IVLBCL was diagnosed by positron emission tomography/computed tomography (PET/CT) before bone marrow biopsy. Immunofixation electrophoresis displayed M proteins positive and IgG kappa light chains that the differential diagnosis should have included both multiple myeloma and IVLBCL. After treatment with rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone and etoposide, the patient's cytokine titres and other laboratory indicators returned to normal. PET/CT showed that complete remission had been achieved. She has been taking zanubrutinib for 1.5 years and remains in remission. This is a report of a patient with hemophagocytic syndrome-associated IVLBCL with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.